Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 32: 1687-1691, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canova-Davis, E.
Right arrow Articles by Kung, V. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canova-Davis, E.
Right arrow Articles by Kung, V. T.

Clinical Chemistry, Vol 32, 1687-1691, Copyright © 1986 by American Association for Clinical Chemistry

Use of a reversed-phase evaporation vesicle formulation for a homogeneous liposome immunoassay

E Canova-Davis, CT Redemann, YP Vollmer and VT Kung

Complement-mediated release of enzyme molecules from reversed-phase evaporation vesicles serves as the basis of the sensitive homogeneous immunoassay reported here. We found it necessary to co-entrap the substrate glucose 6-phosphate with the bacterial enzyme glucose-6- phosphate dehydrogenase (EC 1.1.1.49) to protect enzyme activity during liposome preparation. Enzyme can be released specifically from these liposomes by incubation with antibody and complement. the enzyme is not merely available to substrate but is actually physically free of the liposomes. Inhibition of this complement-mediated lysis by theophylline is the basis for the homogeneous liposome immunoassay described. The assay results vary linearly with theophylline concentrations in plasma in the clinically relevant range, and serum components do not interfere. The reagents in the assay kit are stable for at least seven months when stored at 5 degrees C. No nontheophylline compounds reacted significantly with the antiserum used. The assay can be run in a kinetic format, with either ultraviolet or colorimetric detection.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.